Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

被引：1
|
作者：
Joensuu, H.
Eriksson, M.
Hatrmann, J.
Hall, K. Sundby
Schutte, J.
Reichardt, A.
Schlemmer, M.
Wardelmann, E.
Ramadori, G.
Al-Batran, S.
Nilsson, B. E.
Monge, O.
Kallio, R.
Sarlomo-Rikala, M.
Bono, P.
Leinonen, M.
Hohenberger, P.
Alvegard, T.
Reichardt, P.
机构：
[1] Univ Helsinki, Cent Hosp, Helsinki, Finland
[2] Univ Lund Hosp, S-22185 Lund, Sweden
[3] Univ Klinikum Schleswig Holstein, Kiel, Germany
[4] Oslo Univ Hosp, Oslo, Norway
[5] Marien Hosp Duesseldorf, Dusseldorf, Germany
[6] HELIOS Klinikum Berlin Buch, Sarcoma Ctr Berlin Brandenburg, Berlin, Germany
[7] Univ Munich, Univ Hosp Grosshadern, Munich, Germany
[8] Univ Bonn, Bonn, Germany
[9] Univ Gottingen, D-37073 Gottingen, Germany
[10] Krankenhaus NW Frankfurt, Frankfurt, Germany
[11] Sahlgrens Univ Hosp, Gothenburg, Sweden
[12] Haukeland Hosp, Oslo, Norway
[13] Oulu Univ Hosp, Oulu, Finland
[14] Helsinki Univ Hosp, Helsinki, Finland
[15] 4Pharma, Turku, Finland
[16] Univ Klinikum Mannheim, Mannheim, Germany
[17] Lund Univ, Lund, Sweden
[18] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
    Haas, Naomi B.
    Manola, Judith
    Dutcher, Janice P.
    Flaherty, Keith T.
    Uzzo, Robert G.
    Atkins, Michael B.
    DiPaola, Robert S.
    Choueiri, Toni K.
    JAMA ONCOLOGY, 2017, 3 (09) : 1249 - 1252
  • [22] Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda R.
    Katsaros, Dionyssios
    Bessette, Paul
    Haie-Meder, Christine
    Ottevanger, Petronella B.
    Ledermann, Jonathan A.
    Khaw, Pearly
    Colombo, Alessandro
    Fyles, Anthony W.
    Baron, Marie-Helene
    Kitchener, Henry C.
    Nijman, Hans
    Kruitwagen, Roy F. P. M.
    Jurgenliemk-Schulz, Ina M.
    Nout, Remi A.
    Smit, Vincent T. H. B. M.
    Putter, Hein
    Creutzberg, Carien L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial
    Casali, P. G.
    Le Cesne, A.
    Poveda, A.
    Kotasek, D.
    Rutkowski, P.
    Hohenberger, P.
    Fumagalli, E.
    Judson, I.
    Italiano, A.
    Gelderblom, H.
    Penel, N.
    Kopp, H-G.
    Goldstein, D.
    Martin Broto, J.
    Gronchi, A.
    Wardelmann, E.
    Marreaud, S.
    Zalcberg, J.
    Litiere, S.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.
    Corrie, Philippa
    Marshall, Andrea
    Goonewardena, Madusha
    Dunn, Janet A.
    Middleton, Mark R.
    Nathan, Paul D.
    Gore, Martin Eric
    Davidson, Neville
    Nicholson, Steve
    Kelly, Charles G.
    Marples, Maria
    Danson, Sarah
    Marshall, Ernest
    Houston, Stephen
    Board, Ruth E.
    Waterston, Ashita Marie
    Nobes, Jenny
    Harries, Mark
    Barber, Jim
    Lorigan, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [25] Reply to the manuscript ' A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse' by J.-Y. Blay et al.
    Petrelli, F.
    Dottorini, L.
    Ghidini, A.
    ANNALS OF ONCOLOGY, 2024, 35 (12) : 1206 - 1207
  • [26] Interruption of imatinib (IM) in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival
    Rios, M.
    Lecesne, A.
    Bui, B.
    Adenis, A.
    Bertucci, F.
    Duffaud, F.
    Emile, J.
    Chabaud, S.
    Perol, D.
    Blay, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence
    Kim, Kevin B.
    Legha, Sewa S.
    Gonzalez, Rene
    Anderson, Clay M.
    Johnson, Marcella M.
    Liu, Ping
    Papadopoulos, Nicholas E.
    Eton, Omar
    Plager, Carl
    Buzaid, Antonio C.
    Prieto, Victor G.
    Hwu, Wen-Jen
    Frost, Angela M.
    Alvarado, Gladys
    Hwu, Patrick
    Ross, Merrick I.
    Gershenwald, Jeffrey E.
    Lee, Jeffrey E.
    Mansfield, Paul F.
    Benjamin, Robert S.
    Bedikian, Agop Y.
    MELANOMA RESEARCH, 2009, 19 (01) : 42 - 49
  • [28] Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study.
    Ray-Coquard, I. L.
    Bin Bui, N.
    Adenis, A.
    Rios, M., Sr.
    Bertucci, F.
    Chabaud, S.
    Perol, D.
    Blay, J.
    Le Cesne, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Editorial on "Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial"
    Santoni, Matteo
    Conti, Alessandro
    Montironi, Rodolfo
    Battelli, Nicola
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S74 - S76
  • [30] A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
    Reiss, Kim Anna
    Ahuja, Nita
    Baylin, Stephen
    Mauro, Lauren Ann
    Linden, Sheila
    White, Sharon
    Laheru, Daniel A.
    Herman, Joseph M.
    Wolfgang, Christopher Lee
    Weiss, Matthew J.
    Cameron, John L.
    Makary, Martin
    Azad, Nilofer Saba
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345